Even amid its response to the emergency, the agency went about its business as usual. Bristol-Myers Squibb Co’s BMY 2.48% combo therapy was approved for advanced liver cancer.
Two new molecular entities – Novartis AG’s NVS 0.68% Isturisa oral tablets for adults with Cushing’s disease and Sanofi SA’s SNY 2.17% Sarclisa, in combination with omalidomide and dexamethasone, for the treatment of adult patients with multiple myeloma – were approved during the month.
Here are the key PDUFA dates scheduled for April.
Acceleron, Bristol-Myers Squibb Seek Label Expansion For Anemia Drug
- Company: Acceleron Pharma Inc XLRN 5.09% and Bristol-Myers Squibb Co BMY 2.48%
- Type of Application: sBLA
- Candidate: Luspatercept
- Indication: myelodysplastic syndromes
- Date: April 4
In early December, the companies said the FDA cancelled a review of the BLA by the Oncologic Drugs Advisory Committee, which was scheduled for Dec. 18.
Luspatercept, an erythroid maturation agent, has already been approved for treating anemia in patients with beta thalassemia, who require regular red blood cell transfusions.
Go Or No-Go For Urogen’s Kidney Cancer Drug?
- Company: Urogen Pharma Ltd URGN 1.76%
- Type of Application: NDA
- Candidate: UGN-101 (mitomycin gel)
- Indication: low-grade upper tract urothelial cancer, or LG UTUC
- Date: April 18
“If approved, UGN-101 would be the first non-surgical treatment option for LG UTUC,” the company had said.
FDA To Rule On Sanofi’s Vaccine For Bacterial Form Of Meningitis
- Company: Sanofi SA SNY 2.17%
- Type of Application: BLA
- Candidate: MenQuadfi
- Indication: vaccine for meningococcal meningitis
- Date: April 25
Neurocrine’s Parkinson’s Drug Under FDA Scanner
- Company: Neurocrine Biosciences, Inc. NBIX 5.5%
- Type of Application: NDA
- Candidate: Opicapone
- Indication: Parkinson’s disease
- Date: April 26
Can United Therapeutics’ Drug-Device Combo For Hypertension Scale Regulatory Hurdle?
- Company: United Therapeutics Corporation UTHR 2.31%
- Type of Application: NDA
- Candidate: Trevyent
- Indication: pulmonary arterial hypertension
- Date: April 27
The company, however, indicated in its Feb. earnings release it received a mid-cycle information request from the FDA, noting several deficiencies in the NDA. Although the company has given a written response, based on interactions with the FDA, it said the PDUFA date could be extended beyond April.
Pfizer’s Combo Therapy To Treat Colorectal Cancer Awaits Clearance
- Company: Pfizer Inc. PFE
- Type of Application: sNDA
- Candidate: Braftovi in combination with Bristol-Myers’ Erbitux
- Indication: metastatic colorectal cancer
- Date: April (date not specified)
https://www.benzinga.com/general/biotech/20/03/15665215/attention-biotech-investors-mark-your-calendar-for-these-april-pdufa-dates
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.